(https://www.cnbc.com/2026/08/19/moderna-merck-cancer-vaccine-shows-initial-late-stage-melanoma-data.html) just proved the platform works in late-stage melanoma. That's the easy part. The brutal part? This market scales to $15-20B globally at peak, and institutional buyers are asking a different question: what's the per-patient price, what's the reimbursement path, and how does this compete against every other neoantigen play in the pipeline?

Research these companies